Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.
Company Info
Upcoming Milestones & Key Dates
End-of-Phase 2 meeting with FDA on GSBR-1290 obesity program
GSBR-1290 Phase 3 initiation in obesity
Clinical Development Pipeline
Recent News
Structure Therapeutics' oral GLP-1 pill produced a 'relatively underwhelming' but still positive Phase 2 readout in diabetes, with analysts questioning commercial viability against Lilly's Foundayo and Novo's Wegovy pill.
Leadership Team
Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings